molecular imaging News
-
Akrotome Co-Founder Makes International Presentations
Akrotome Co-Founder, Dr. Jim Basilion, traveled to Europe to make invited presentations in November, 2018. Dr. Basilion delivered papers focused on the use of molecular probes for guided, precision surgery to the European Society of Molecular Imaging, the World Society of Molecular Imaging, and the Netherlands Science ...
-
Edinburgh Molecular Imaging are part of a EPSRC funded consortium
Edinburgh Molecular Imaging is part of an EPSRC funded consortium, led by Dr Jon Shephard of Heriot-Watt University in collaboration with Professor David Jayne from the University of Leeds to develop a revolutionary new bowel cancer surgery tool that will enable surgeons to carry out operations with far greater ...
-
Akrotome Co-Founder attends workshop in Washington DC
Akrotome Co-Founder Dr. James Basilion attended the World Molecular Imaging Congress/National Cancer Institute workshop in Washington DC. The workshop included participants from FDA and the Centers for Medicare & Medicaid Services (CMS). Focused on the PET/ultrasound/optical agent approval process, the invitation-only workshop was attended by leaders from government agencies, academia, and ...
-
Meet us at the WMIC 2022, September 28 - October 1 in Miami, Florida, USA
Check out the advantages that our specialized imaging agents can provide to your research! Come and visit at the World Molecular Imaging Congress (WMIC) 2022 in Miami to discover our innovative range of Viscover products and their exciting application possibilities. We look forward to seeing you to discuss your diagnostic imaging needs and to share the latest experiences in pre-clinical ...
-
Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer
Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately. Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham ...
-
Edinburgh Molecular Imaging Ltd appoints new Chairman
The Board of Edinburgh Molecular Imaging Ltd (EM Imaging) is pleased to announce the appointment of John Jeans CBE CEng as non-executive Chairman with effect from 31st August 2015. In an industrial career spanning 35 years John held senior international leadership positions in global companies including Smith & Nephew, Bristol Myers Squibb, Johnson & Johnson and Amersham plc (now GE ...
-
Edinburgh Molecular Imaging Closes Financing
Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance new molecular targeted systemic radiotherapy agents, EMT-100 and EMT-101 to be ready for clinic development. Current investors and one new investor supported the round. EMT-100 and EMT-101 have been developed as ...
-
Mauna Kea Technologies Participates in Dutch Molecular Imaging Consortium that was Awarded €5.4 Million
MEDPHOT consortium aims to develop light-based molecular imaging solution for pulmonary diseases Mauna Kea Technologies today announced it is part of a molecular imaging consortium that was awarded €5.4 million by the Perspective Program of the Netherlands Organization for Scientific Research (NWO). Molecular imaging provides insight into molecular and cellular processes in the body, and ...
-
EM Imaging obtains global licence for optical agent that detects cancer early
Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer. EM Imaging, a company which develops and commercialises novel optical imaging agents, recently signed the licensing agreement with GE Healthcare Ltd. and Dyax Inc. EM Imaging will now complete the ...
-
Edinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and advanced visualisation ...
-
MultiModal Molecular Imaging Institute at Maastricht University Joins Waters Centers of Innovation Program
At a ceremony and symposium at Maastricht University, The Netherlands, Waters Corporation (NYSE:WAT) officially welcomed the Maastricht MultiModal Molecular Imaging Institute M4I into the Waters Centers of Innovation (COI) Program. Under the direction of Professor Ron Heeren, the institute conducts research into applications for mass spectrometry in three main areas: oncology, neurology and ...
-
Mauna Kea Technologies Receives FDA Clearance and CE Marking For Its Next-Generation Cellvizio® Platform
The new Cellvizio®platform includes significant improvements and will enable major innovations Mauna Kea Technologies announced today that it has obtained 510(k) clearance (K193416) from the U.S. Food and Drug Administration (FDA) and CE marking of the next-generation Cellvizio® endomicroscopy platform, built with the company’s new proprietary system architecture. This marks the ...
-
Zionexa us corp. Secures permanent hcpcs code for cerianna
Zionexa US Corp., a wholly owned subsidiary of Zionexa SAS, specialized in the development and commercialization of in-vivo biomarkers for use in guiding targeted therapies in oncology, announced that Cerianna has been assigned a permanent Healthcare Common Procedure Coding System (HCPCS) code A9591 “Fluoroestradiol F 18, diagnostic, 1 millicurie” effective January 2021. Cerianna ...
By Zionexa
-
FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
By SOFIE
-
First Cerianna Doses Distributed in San Francisco Area
Zionexa US Corp., a wholly owned subsidiary of Zionexa SAS, specialized in the development and commercialization of in-vivo biomarkers for use in guiding targeted therapies in oncology, announced that the first Cerianna (Fluroroestradiol F-18) doses have been distributed to two oncology imaging centers in the San Francisco area. These two doses of Cerianna represent the future for two breast ...
By Zionexa
-
Zionexa us corp. Secures pass-through payment status and assignment of temporary c-code for cerianna
Zionexa US Corp., a wholly owned subsidiary of Zionexa SAS, specialized in the development and commercialization of in-vivo biomarkers for use in guiding targeted therapies in oncology, announced that the Center for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and reimbursement through a C-code for Cerianna (fluoroestradiol F-18) injection. Cerianna ...
By Zionexa
-
ODS Medical, Inc. closes a new financing round to further support product development diversification of applications
ODS Medical, Inc., a Montreal based medical technology company, is pleased to announce a new financing round to support product engineering and regulatory work. ODS Medical is bringing together the power of machine learning and molecular imaging to develop optical biopsy tools based on Raman spectroscopy. These tools are bringing real time tissue characterization to operating rooms and diagnostic ...
-
SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial
SurgiMab and Quest Medical Imaging, a leader in the market for multispectral cameras, announced today that they have entered into a collaboration agreement for the upcoming Phase III clinical trial of Surgimab’s SGM-101 in fluorescent guided colorectal cancer surgery. Under the terms of the agreement, Quest Medical Imaging has received an undisclosed lump sum payment to provide 12 ...
By SurgiMab
-
Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination
The Cellvizio®100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Cellvizio® 100 series and all associated Confocal Miniprobes™ for ...
-
The MALDI-Imaging Lipidomics Service Is Now Available Through Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The company has recently announced the fully-developed MALDI-Imaging Lipidomics Service to research the distribution of lipids in tissues. Lipidomics MALDI imaging mass ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you